Sila Oksuz - Publications

Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group.

Journal: Journal of clinical medicine

Published: June 01, 2026

Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study.

Journal: BMC cancer

Published: March 02, 2026

Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 01, 2026

Pan-immune-inflammation value as a prognostic and predictive biomarker in metastatic non-small cell lung cancer treated with nivolumab: A real-world study.

Journal: Oncology letters

Published: February 05, 2026

Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.

Journal: Journal of clinical medicine

Published: January 26, 2026

Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study.

Journal: Journal of personalized medicine

Published: December 09, 2025

Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma.

Journal: Journal of cancer research and clinical oncology

Published: November 24, 2025

Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study.

Journal: Medicina (Kaunas, Lithuania)

Published: November 21, 2025

Impact of body mass index on progression-free survival and endocrine immune-related adverse events in advanced NSCLC patients treated with nivolumab: A retrospective cohort study.

Journal: Northern clinics of Istanbul

Published: September 03, 2025

Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage.

Journal: Journal of clinical medicine

Published: August 18, 2025

Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC).

Journal: Healthcare (Basel, Switzerland)

Published: April 15, 2025

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine.

Journal: Medicina (Kaunas, Lithuania)

Published: March 18, 2025